Omega Therapeutics, Inc.
OMGA · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.11 | 0.81 | 0.27 |
| FCF Yield | -20.85% | -10.53% | -6.99% | -10.97% |
| EV / EBITDA | -10.05 | -12.85 | -13.10 | -11.94 |
| Quality | ||||
| ROIC | -11.37% | -9.73% | -11.69% | -10.73% |
| Gross Margin | 100.00% | -337.68% | 23.05% | -80.08% |
| Cash Conversion Ratio | 0.85 | 0.78 | 0.59 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 76.07% | 92.29% | 128.87% | 178.03% |
| Free Cash Flow Growth | -7.37% | -5.90% | 32.20% | 23.40% |
| Safety | ||||
| Net Debt / EBITDA | -5.95 | -5.08 | -3.63 | -3.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 5.88 |
| Cash Conversion Cycle | 16.75 | 15.20 | -32.11 | 569.18 |